These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 32910820)

  • 21. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
    Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage.
    Amor S; Fernández Blanco L; Baker D
    Clin Exp Immunol; 2020 Nov; 202(2):193-209. PubMed ID: 32978971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host-directed therapies: a potential solution to combat COVID-19.
    Baindara P; Agrawal S; Mandal SM
    Expert Opin Biol Ther; 2020 Oct; 20(10):1117-1120. PubMed ID: 32783643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 and interferon blockade.
    Diamond B; Volpe BT; VanPatten S; Al Abed Y
    Mol Med; 2020 Nov; 26(1):103. PubMed ID: 33167852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-Free Therapies: Novel Approaches for COVID-19.
    Maron-Gutierrez T; Rocco PRM
    Front Immunol; 2020; 11():583017. PubMed ID: 33072130
    [No Abstract]   [Full Text] [Related]  

  • 26. COVID-19: The Immune Responses and Clinical Therapy Candidates.
    Zhand S; Saghaeian Jazi M; Mohammadi S; Tarighati Rasekhi R; Rostamian G; Kalani MR; Rostamian A; George J; Douglas MW
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32756480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishing a Unified COVID-19 "Immunome": Integrating Coronavirus Pathogenesis and Host Immunopathology.
    Wauters E; Thevissen K; Wouters C; Bosisio FM; De Smet F; Gunst J; Humblet-Baron S; Lambrechts D; Liston A; Matthys P; Neyts J; Proost P; Weynand B; Wauters J; Tejpar S; Garg AD
    Front Immunol; 2020; 11():1642. PubMed ID: 32719686
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19).
    Laterre PF; François B; Collienne C; Hantson P; Jeannet R; Remy KE; Hotchkiss RS
    JAMA Netw Open; 2020 Jul; 3(7):e2016485. PubMed ID: 32697322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The trinity of COVID-19: immunity, inflammation and intervention.
    Tay MZ; Poh CM; Rénia L; MacAry PA; Ng LFP
    Nat Rev Immunol; 2020 Jun; 20(6):363-374. PubMed ID: 32346093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19.
    Dong H
    Cancer Immunol Immunother; 2020 Jun; 69(6):911-912. PubMed ID: 32347359
    [No Abstract]   [Full Text] [Related]  

  • 32. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review.
    Razmi M; Hashemi F; Gheytanchi E; Dehghan Manshadi M; Ghods R; Madjd Z
    Int Immunopharmacol; 2020 Nov; 88():106942. PubMed ID: 32896750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity, COVID-19 and immunotherapy: the complex relationship!
    Finelli C
    Immunotherapy; 2020 Oct; 12(15):1105-1109. PubMed ID: 32677493
    [No Abstract]   [Full Text] [Related]  

  • 35. COVID-19: an Immunopathological View.
    Kadkhoda K
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32321823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Covid-19: Perspectives on Innate Immune Evasion.
    Taefehshokr N; Taefehshokr S; Hemmat N; Heit B
    Front Immunol; 2020; 11():580641. PubMed ID: 33101306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.
    Abid MB; Mughal M; Abid MA
    JAMA Oncol; 2020 Oct; 6(10):1529-1530. PubMed ID: 32433719
    [No Abstract]   [Full Text] [Related]  

  • 38. Complement as a target in COVID-19?
    Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
    Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
    Napp LC; Bauersachs J
    Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
    [No Abstract]   [Full Text] [Related]  

  • 40. Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2.
    Renn A; Fu Y; Hu X; Hall MD; Simeonov A
    Trends Pharmacol Sci; 2020 Nov; 41(11):815-829. PubMed ID: 32829936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.